These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 2342174

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Fibrosis of tunica albuginea: complication of long-term intracavernous pharmacological self-injection.
    Hu KN, Burks C, Christy WC.
    J Urol; 1987 Aug; 138(2):404-5. PubMed ID: 2439714
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intracavernous drug delivery system: an alternative to intracavernous injection in the treatment of impotence?
    Stief CG, Wetterauer U, Kulvelis F, Popken G, Staubesand J, Sommerkamp H.
    Urol Int; 1990 Aug; 45(6):321-5. PubMed ID: 2288047
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W, Lycklama à Nijeholt AA, Kropman RF, Vermeij P, Zwartendijk J.
    Eur Urol; 1994 Aug; 26(4):319-21. PubMed ID: 7713130
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S.
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract] [Full Text] [Related]

  • 9. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R, Asakawa M, Kawashima H, Yoshimura R, Maekawa T, Kashiwara N, Tanaka H, Nishio S.
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [Abstract] [Full Text] [Related]

  • 10. [Intracavernous pharmacotherapy for organic impotence in the elderly].
    Richter S, Shalev M, Nissenkorn I.
    Harefuah; 1990 Aug; 119(3-4):66-7. PubMed ID: 2227669
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of fibrotic penile lesions secondary to the intracorporeal injection of vasoactive agents.
    Corriere JN, Fishman IJ, Benson GS, Carlton CE.
    J Urol; 1988 Sep; 140(3):615-7. PubMed ID: 3411687
    [Abstract] [Full Text] [Related]

  • 17. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W, de la Fuente RB, Lycklama à Nijeholt AA, Vermeij P, Zwartendijk J.
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [Abstract] [Full Text] [Related]

  • 18. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM, Stevenson RW, Szasz G.
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [Abstract] [Full Text] [Related]

  • 19. Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.
    Wyndaele JJ, de Meyer JM, de Sy WA, Claessens H.
    Paraplegia; 1986 Oct; 24(5):271-5. PubMed ID: 3774363
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologically induced erections among geriatric men.
    Kerfoot WW, Carson CC.
    J Urol; 1991 Oct; 146(4):1022-4. PubMed ID: 1895417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.